Q: Is an effort to drive sens lower? Schlange: What TracerX is doing; case studies are good, but larger cohorts needed. #MDxEU17
1:03pm April 11th 2017 via Hootsuite
Schlange: Need to have a workflow from pt sample to data back to physician. Impt for a workflow for clinical implementation #MDxEU17
12:58pm April 11th 2017 via Hootsuite
Schlange: Key issue for liq biopsy is clinical utility. And pre-analytical req's are needed. To use standards 'as much as possible' #MDxEU17
Schlange: For circulating miRNA markers, may even be more challenging, even the right time of the day for sample collection #MDxEU17
12:57pm April 11th 2017 via Hootsuite
Schlange: Shows extensive list of standards and technologies, incl fragmentase from NEB, or Sequins from AUS, or IDT synthetics #MDxEU17
12:56pm April 11th 2017 via Hootsuite
Schlange: Efficiency of extraction, use of standards for NGS panels (@SeraCare) and need for bioinformatics stnds #MDxEU17
12:55pm April 11th 2017 via Hootsuite
Schlange: Other initiatives - IBLL/LIH, SPIDIA-4P, IQNPath. (He lists website links.) ctDNA RING studies - tube selection #MDxEU17
12:54pm April 11th 2017 via Hootsuite
Schlange: ISO guidleines - 2-8C, but less hemolysis at RT. Spin 2x is better, may be less feasible clinically #MDxEU17
12:53pm April 11th 2017 via Hootsuite
Schlange: Little data on what blood volumes people can get in the first place. From cobas - similar percentages. CAPP-Seq to 0.02% #MDxEU17
12:52pm April 11th 2017 via Hootsuite
Schlange: Prior was for metastatic. For localized - 30-50%. NSCLC - 60^ of Stg I/II, can get mean AF 2%. #MDxEU17
12:51pm April 11th 2017 via Hootsuite
Schlange: Showed slide from Bettegowda '14 STM 85-95% of cancer cases where ctDNA is detected (CRC, Panc, Breast, Gastric) #MDxEU17
12:49pm April 11th 2017 via Hootsuite
Schlange: Most impt - repro. Shows data of recovery with CellSerch, negative recovery of EpCAM neg, and Siemens tech #MDxEU17
12:48pm April 11th 2017 via Hootsuite
Schlange: CTC RING study - spike-in samples shipped to 3 sites, yield, cp to CellSearch. Heterogeneity; purify (WBC backgnd) #MDxEU17
12:47pm April 11th 2017 via Hootsuite
Schlange: Wanted to have no new assays - just how to best combine tech and use them clinically. #MDxEU17
12:46pm April 11th 2017 via Hootsuite
Schlange: Molecular char of NSCLC cell lines - ID a panel of cell lines at different EpCAM, EGFR, KRAS status #MDxEU17
12:45pm April 11th 2017 via Hootsuite
Schlange: Feels that the FDA is keenly interested, wants to be involved at the advisory level. #MDxEU17
12:44pm April 11th 2017 via Hootsuite
Schlange: Protocols, output formats, results and comparing them - all different. 1.5y ago a "critical path innovation mtg" #MDxEU17
Schlange: Lung ca and HER2 Rx resistant BC has started. Same technology at different sites. #MDxEU17
12:43pm April 11th 2017 via Hootsuite
Schlange: need to look at primary tumor, clin outcome, treatment response, ctDNA status. Want to prove clin utilty #MDxEU17
12:42pm April 11th 2017 via Hootsuite
Schlange: Ultimate proof may be from genetic information at single-cell level. SOP from pre-analytic sample handling. #MDxEU17
12:41pm April 11th 2017 via Hootsuite
Schlange: 2nd indication: HER2+, treatment refractory breast cancer. CellSearch already approved. Est criteria for detection #MDxEU17
12:40pm April 11th 2017 via Hootsuite
Schlange: 3 ongoing clinical trials - TracerX, Netherlands Trial, EORTC Spectralung. Larger population of samples. #MDxEU17
12:39pm April 11th 2017 via Hootsuite
Schlange: 35 partners, companies in US, Singapore. One indication: NSCLC, easy to agree on. Est of 7.5mL, only 10% will have >1CTC #MDxEU
Schlange: IMI is meeting high unmet need, Pharma + EU commission. 3.3B € funding through 2024. #MDxEU17
12:37pm April 11th 2017 via Hootsuite
Schlange: Gilupi with a wire collection device, diagnostic apheresis. Goal: >50 living CTCs in >50% of pts #MDxEU17
12:35pm April 11th 2017 via Hootsuite
Schlange: 1/2 of drugs have assoc'd biomarker. CTC for mBC, mMelanoma, mCRC. More markers - Seimens, Apocell, Fluxion, Biocept #MDxEU17
12:34pm April 11th 2017 via Hootsuite
Schlange: Multi-center studies need short proc time, reasonable costs. CTCs have one approved test (CellSearch) #MDxEU17
12:33pm April 11th 2017 via Hootsuite
Schlange: Want early dx, pt stratification; early signs of efficacy. Early ID of drug resist. #MDxEU17
12:32pm April 11th 2017 via Hootsuite
Schlange: The int'l coordinator of IMI's CANCER ID: website https://t.co/hS2PKXuDOK CTCs, ctDNA, miRNA as blood-based biomarkers #MDxEU17
12:31pm April 11th 2017 via Hootsuite
Thomas Schlange (Bayer DE) Standardization of ctDNA analysis for use in the clinical setting under the umbrella of CANCER-ID #MDxEU17
12:29pm April 11th 2017 via Hootsuite
Q: Where would neg samples come from in hosp setting? Habermann: There are cohorts available from biobanks, also healthy pts #MDxEU17
12:28pm April 11th 2017 via Hootsuite
Habermann: (Review article '15 of biobanking storage conditions https://t.co/5b3Qe8J5fy -80C not good for RNA?) #MDxEU17
12:26pm April 11th 2017 via Hootsuite
Habermann: Patient consent, biobank's data updated by the clinical phenotyping data (2K parameters) #MDxEU17
12:22pm April 11th 2017 via Hootsuite
Habermann: 3 international organizations for biobanking: ESBB, BBMRI, ISBER, first int'l meeting in Stockholm in Sept '17. #MDxEU17
12:18pm April 11th 2017 via Hootsuite
Habermann: Low degree of standardization for isolation, assessment. Could be implemented in biobanking workflows. #MDxEU17
12:16pm April 11th 2017 via Hootsuite
Habermann: #MDxEU17 Exosome enrichment review '16 https://t.co/KfNa8PNZbL Exoquick not evaluated before, shows data via PCA
12:15pm April 11th 2017 via Hootsuite
Habermann: Exosomes have potential for Dx, many isolation methods (ultracentrifgure, exoquick) #MDxEU17
12:14pm April 11th 2017 via Hootsuite
Habermann: cfDNA fragmentation, difference in amount, isolation methods. No std handlling, or preanalytical handling #MDxEU17
12:13pm April 11th 2017 via Hootsuite
Habermann: #MDxEU17 REMARK ref from '06 https://t.co/sC8lT9dWDF Onto cfDNA: several sources, structural forms (exosomes etc)
12:12pm April 11th 2017 via Hootsuite
Habermann: Want to dev a CTC-Guide, 3 different guidelines (REMARK, '05, STARD, '03, CONSORT) 2.2 preanalytical conditions #MDxEU17
12:11pm April 11th 2017 via Hootsuite
Habermann: Concl: high diversity in terms of processing, storage and reporting, but still high value as prognostic markers #MDxEU17
12:09pm April 11th 2017 via Hootsuite
Habermann: Reviewed all the variability in blood quality management - 37% EDTA, 73% peripheral, 27% central #MDxEU17
Habermann: 17 different markers for qRT-PCR method alone. 40% didn't use controls. One study n=735 no controls #MDxEU17
12:08pm April 11th 2017 via Hootsuite
Habermann: The challenge of tumor heterogeneity, as well as the reprod of marker data. Lit review for 71 studies of CTCs in CRC #MDxEU17
12:07pm April 11th 2017 via Hootsuite
Jens Habermann (Univ Lubeck GE) Standardization of liquid biopsies for prec med in oncology: a task for clinical biobanks? #MDxEU17
12:04pm April 11th 2017 via Hootsuite
Q: Interlab lower limit? Devonshire: Methods are down to 0.1% #MDxEU17
12:03pm April 11th 2017 via Hootsuite
DevonshireL Credits include Adam Corner of @RainDanceTech , and Patricia Hegerich at @thermofisher #MDxEU17
11:59am April 11th 2017 via Hootsuite
Devonshire: Raises the point, perhaps a ref std from their reference lab would cut across groups, instead of linearly (orig diag) #MDxEU17
11:58am April 11th 2017 via Hootsuite
Devonshire: Issues were at the software analysis stage. Details in this '17 ref https://t.co/cx1WH7dV32 #MDxEU17
11:53am April 11th 2017 via Hootsuite
Devonshire: Looking across 21 labs all using QX200, without calibration good agreement of WT. For KRAS, found 3 outlier labs #MDxEU17
11:52am April 11th 2017 via Hootsuite
